News

In its draft guidance, the National Institute of Health and Care Excellence said that the benefits of Praluent are uncertain. The draft guidance has not recommended alirocumab, alone

One of these medicines, fulvestrant (Faslodex) for advanced breast cancer, was accepted following consideration under the SMC’s Patient and Clinician Engagement Process (PACE), which aims to improve patient

The recent orphan drug designations of Ampligen® for Ebola and Alferon® N for MERS viruses by the European Regulatory authorities demonstrates the global need for drugs that possess

ORION is a randomized, double-blind, placebo-controlled study exploring the metabolic effects of cenicriviroc (CVC) in obese adults (BMI greater than or equal to 30 kg/m2) with prediabetes or

Following the issuance of the Company’s February 8, 2016, press release describing the partial clinical hold issued by the U.S. Food and Drug Administration (FDA) regarding those clinical

The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups. The clinical trial commenced in February 2012 at

The pay-for-performance agreements are expected to set pricing on certain drugs based on how they work for certain patients. In July 2015, the US Food and Drug Administration

The company said that it was informed by FDA that it will require another three months to complete its New Drug Application (NDA) review for eteplirsen. Sarepta received

Pharming entered into the original exclusive distribution agreement with Cytobioteck in May 2015 for the distribution of RUCONEST(R) in Colombia and Venezuela. Under the extended agreement, Cytobioteck will